Follitropin alfa biosimilar - GEMA

Drug Profile

Follitropin alfa biosimilar - GEMA

Alternative Names: Folitime; r-hFSH biosimilar - GEMA; recombinant humanfollicle stimulating hormone - GEMA

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator GEMA
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Female infertility

Most Recent Events

  • 01 Dec 2016 GEMA completes a phase III trial in Female infertility in Argentina (SC) (NCT02454556)
  • 01 Apr 2015 Phase-III clinical trials in Female infertility in Argentina (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top